Biotech Losers: Amicus Therapeutics, Fonar, Agilent, St. Jude Medical, Hospira

Los Angelas, CA -- (SBWIRE) -- 02/16/2013 -- Amicus Therapeutics (NASDAQ::FOLD) down 27.5 percent. Amicus issued additional 6-month (Stage 1) results from the first ongoing Phase 3 global registration study (Study 011) of investigational oral migalastat HCl monotherapy (150 mg, every-other-day) in males and females with Fabry disease who had genetic mutations identified as amenable to migalastat HCl in a cell-based assay.

Should FOLD a Buy or Sell Now? Find Out Here

Fonar Corporation (NASDAQ:FONR) fell 3.29% and is trading at $5.58. Designs, develops, manufactures and markets magnetic resonance imaging (MRI) scanners which utilize non-superconductive magnetic technology for the detection and diagnosis of human diseases. The scanners create cross-sectional images of human body which are used to detect and diagnose human disease

Can FONR Rebound After The Recent Slump and Investors Can Make Money? Find Out Here

Agilent Technologies (NYSE:A) gapped open slightly lower Friday and declined throughout the first half of the session. Shares finished down by 2.33 at $42.25 on the highest volume of the year. The stock fell to over a one-month low and slipped beneath its 50-day moving average.

How Should Investors Trade A After The Recent Volatile Moves? Find Out Here

St. Jude Medical (NYSE:STJ) opened at 43.01 on Friday. St. Jude Medical has a 52-week low of $30.25 and a 52-week high of $44.80. The stock’s 50-day moving average is currently $39.61. The company has a market cap of $13.333 billion and a price-to-earnings ratio of 18.00.

How Should Investors React To STJ Now? Find Out Here

Hospira, Inc. (NYSE:HSP) shares decreased 7.96% to $30.05. The company, on Feb. 13, announced that for fiscal 2013, it expects net sales growth to be in a range of 1% to 3% on both a constant-currency and reported basis and adjusted earnings per share (EPS) to be in a range of $2.05 to $2.20, representing growth of 2% to 9%. The Company reported revenue of $4.092 billion for fiscal 2012.

Is HSP Showing Any Sign of Buy At The Current Market Price? Find Out Here

DISCLAIMER:
Neither HotPennyStockNews.com nor its owners, operators, affiliates or anyone disseminating information on its behalf is registered as an Investment Advisor or broker dealer in any jurisdiction whatsoever and none of the information provided by HotPennyStockNews.com, owners, operators, affiliates or anyone disseminating information on its behalf should be construed as investment advice or an investment recommendation. HotPennyStockNews.com makes no recommendation that the securities of the companies profiled should be purchased, sold or held by individuals or entities that learn of the profiled companies through HotPennyStockNews.com. Investing in securities is speculative and carries a high degree of risk and no investment should be made unless you can afford to lose your entire investment. It is possible that an investor's entire investment may be lost or impaired due to the speculative nature of the companies profiled. Please consult a broker before purchasing or selling any securities viewed on or mentioned herein..

Contact:
hotpennystocknews.com
info@hotpennystocknews.com